Promore Pharma AB (publ) comments that a number of measures have been taken to reduce the Company's costs, which includes the discontinuation of the ensereptide project and the termination of the Company's key personnel. The board of Promore Pharma has therefore made the decision to give notice of termination to CFO Erik Magnusson.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.5 SEK | -5.66% | -10.71% | -29.58% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.58% | 15.51M | |
+7.72% | 113B | |
+10.67% | 106B | |
+0.41% | 22.27B | |
-11.93% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-4.92% | 17.24B | |
+6.69% | 14.29B | |
+35.78% | 12.52B |
- Stock Market
- Equities
- PMDS Stock
- News PMD Device Solutions AB
- Promore Pharma AB Announces CFO Change